The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis.

The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Mar; 84(3):676-690.

View in: PubMed

subject areas

Antibodies, Monoclonal
Autoimmune Diseases
Humans
Interleukin-12
Interleukin-23
Lung Diseases, Interstitial
Randomized Controlled Trials as Topic
Respiratory Tract Infections

authors with profiles

Dejan Micic